Our Story
We combine our deep technological expertise in plant biotech, pharmaceutical production, and clinical development, to create pharmaceutical candidates for the highly unmet medical needs.
BaiyaPharming™ platform has the flexibility to produce biopharmaceutical products of interest within weeks, compared to the conventional process of taking months to years. This results in our process being faster and lower in cost for the research and development of products, such as cosmetic raw materials, diagnostic test kit materials, including those for the complex therapeutics treating cancer and infectious diseases.
We have been scaling up our platform from scratch to hatch within our tiny laboratory since its founding in 2018. Currently, we have established a cGMP facility in Bangkok, Thailand to produce the clinical materials of our plant-produced proteins, with the capacity of a production of COVID-19 vaccine up to 5 million doses per month.
Over the years, the collaboration of our team’s expertise in plant biotechnology, biopharmaceutical production and clinical development has driven our company towards achieving a broad portfolio of trademarked biologic candidates, advancing and strengthening our pipeline. Our visions are to be a global leader and front runner of innovation and excellence using the plant-based technology platform. We aim to change people’s lives by leading the biotech ecosystem forward by being agile, highly-networked and committed to the core values.
Baiya Phytopharm – MP Solution –
BGF Plantrix
To align with the specific strategic objectives of the company, Baiya Phytopharm organizes itself into three independent entities that own management structure with technological support from Baiya Phytopharm: MP Solution and BGF Plantrix.
MP Solution assists clients in efficiently launching their products into the market
We offer services that assist clients in efficiently launching their products into market by providing cost-efficient options for contract manufacturing, development, and testing, all while adhering to regulatory guidelines. Molecular Pharming Solution (MP Solution) is the appointed body responsible for executing these activities.
Our ServicesBGF Plantrix utilizes advanced technology to supply and create products using growth factors, cytokines, and more.
BGF Plantrix is devoted to rendering growth factors and cytokines to not only be more affordable, but also widely accessible, while prioritizing the efficacy and bioactivity of our offerings. As trailblazers in using plants for production, our impact spans various industries, including alternative meats, cosmetic raw materials, and support materials for gene and cell therapy. Our venture into the cosmetics industry underscores our commitment to providing superior beauty solutions. Utilizing plant-derived growth factors, we are embarking on quick-win projects and creating customized solutions to meet the specific demands of this evolving market.
Our ProductsCOVID-19 Vaccines
When COVID-19 hit Thailand in late 2019, the company has publicly crowdfunded from the Thai community to support its research and development of COVID-19. With support from the Thai government, the company has successfully established its own manufacturing facility. Baiya’s scientists raced against the clock, working on the prototype of our COVID-19 vaccine, “Baiya-SARS-CoV-2-Vax 1”, which contains a recombinant RBD protein of the SARS-CoV-2 virus.
During the progression of pandemic worldwide, In July of 2021, amidst the progression of the worldwide pandemic, our Baiya-SARS-CoV-2-Vax 1 became the first plant-derived COVID-19 vaccine entering human clinical trials in Asia, followed by our second candidate “SARS-CoV-2-Vax 2” in which was modelled after the first prototype.
This First-in-Human clinical trial of Baiya SARS-CoV-2-Vax 2 began in March 2022 to evaluate the vaccine’s safety when administered to healthy adults. After promising results, the trial has been recommended to continue.
GMP Certified
ISO 9001:2015
